{"id":"aflibercept-eylea","safety":{"commonSideEffects":[{"rate":"25–30","effect":"Conjunctival hemorrhage"},{"rate":"10–15","effect":"Eye pain"},{"rate":"10–15","effect":"Floaters"},{"rate":"5–10","effect":"Intraocular pressure elevation"},{"rate":"<1","effect":"Endophthalmitis"},{"rate":"<1","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their endothelial cell receptors, thereby suppressing pathological neovascularization and vascular permeability. This mechanism is particularly effective in ocular conditions where abnormal blood vessel growth drives vision loss.","oneSentence":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:19.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT02298959","phase":"PHASE1","title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-04-08","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":59},{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT04515524","phase":"","title":"Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-02-05","conditions":"Retinopathy of Prematurity","enrollment":100},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":"Macular Neovascularization Secondary to Age-Related Macular Degeneration","enrollment":480},{"nctId":"NCT07489586","phase":"PHASE3","title":"A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":356},{"nctId":"NCT07489131","phase":"PHASE3","title":"Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Alvotech Swiss AG","startDate":"2026-03","conditions":"Diabetic Macular Edema","enrollment":256},{"nctId":"NCT07482176","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2026-03-16","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":284},{"nctId":"NCT06315556","phase":"","title":"An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-03-05","conditions":"Retinopathy of Prematurity, Preterm Infants","enrollment":200},{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":40},{"nctId":"NCT06893965","phase":"NA","title":"Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-07-08","conditions":"Macular Diseases","enrollment":100},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT07362927","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Diabetic Macular Edema (DME)","enrollment":32},{"nctId":"NCT06929143","phase":"","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-04-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)","enrollment":3000},{"nctId":"NCT06196840","phase":"PHASE2","title":"Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2024-01-24","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":50},{"nctId":"NCT07317934","phase":"PHASE3","title":"Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)","status":"RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2026-01-14","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":332},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06075147","phase":"","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-02-15","conditions":"Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)","enrollment":2500},{"nctId":"NCT05705258","phase":"","title":"A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-03-27","conditions":"Retinopathy of Prematurity, Newborns, Infants","enrollment":75},{"nctId":"NCT06850922","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-06-22","conditions":"Diabetic Macular Edema","enrollment":546},{"nctId":"NCT04519619","phase":"","title":"Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-11-27","conditions":"Neovascular Glaucoma","enrollment":480},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT07440225","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT07434713","phase":"","title":"EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-07-14","conditions":"Age-Related Macular Degeneration (AMD)","enrollment":50},{"nctId":"NCT07423429","phase":"","title":"Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02","conditions":"Exudative Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT07340372","phase":"","title":"Home Monitoring in eAMD Treatment","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-03","conditions":"Exudative Age-Related Macular Degeneration","enrollment":80},{"nctId":"NCT07390253","phase":"","title":"Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2024-09-18","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":50},{"nctId":"NCT05197270","phase":"PHASE1, PHASE2","title":"4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2021-12-09","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":215},{"nctId":"NCT06550011","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avirmax Biopharma Inc","startDate":"2024-08-07","conditions":"Neovascular (Wet) AMD","enrollment":18},{"nctId":"NCT07064759","phase":"PHASE3","title":"Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-07-22","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":480},{"nctId":"NCT04645212","phase":"","title":"Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-12-14","conditions":"Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":23},{"nctId":"NCT07389980","phase":"PHASE3","title":"Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial","status":"RECRUITING","sponsor":"Yeungnam University College of Medicine","startDate":"2026-12-24","conditions":"Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)","enrollment":50},{"nctId":"NCT04663750","phase":"PHASE3","title":"Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2021-04-16","conditions":"Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage","enrollment":210},{"nctId":"NCT04787341","phase":"PHASE2","title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-12-15","conditions":"Colorectal Cancer","enrollment":214},{"nctId":"NCT06321302","phase":"PHASE2","title":"A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-05-15","conditions":"Diabetic Retinopathy","enrollment":178},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":"AMD","enrollment":30},{"nctId":"NCT07365371","phase":"PHASE4","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-01","conditions":"Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)","enrollment":174},{"nctId":"NCT03845049","phase":"PHASE3","title":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-03","conditions":"Macular Telangiectasia","enrollment":16},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":"Diabetic Macular Edema (DME)","enrollment":116},{"nctId":"NCT05769153","phase":"PHASE1, PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":140},{"nctId":"NCT06422507","phase":"PHASE3","title":"A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-05-29","conditions":"Diabetic Macular Edema","enrollment":333},{"nctId":"NCT04311606","phase":"PHASE2","title":"Anti-VEGF Therapy for Acute Thyroid Eye Disease","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-11-02","conditions":"Thyroid Eye Disease","enrollment":11},{"nctId":"NCT07301775","phase":"PHASE4","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ahmad Zeeshan Jamil","startDate":"2026-01-01","conditions":"Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract","enrollment":166},{"nctId":"NCT05850520","phase":"PHASE3","title":"A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-05-15","conditions":"Macular Edema Secondary to Retinal Vein Occlusion","enrollment":892},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT07235527","phase":"","title":"Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-11-20","conditions":"Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration, Anti Vascular Endothelial Growth Factor","enrollment":54},{"nctId":"NCT04932980","phase":"NA","title":"Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Berner Augenklinik","startDate":"2022-05-09","conditions":"Wet Age-related Macular Degeneration","enrollment":80},{"nctId":"NCT06121180","phase":"PHASE2","title":"Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-04","conditions":"Metastatic Uveal Melanoma","enrollment":32},{"nctId":"NCT03006081","phase":"PHASE2","title":"The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-04-14","conditions":"Diabetic Retinopathy","enrollment":38},{"nctId":"NCT04101877","phase":"PHASE2","title":"The Sahlgrenska Anti-VEGF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2020-09-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":402},{"nctId":"NCT07205887","phase":"PHASE2","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","status":"RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2025-09-12","conditions":"Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)","enrollment":160},{"nctId":"NCT06856577","phase":"PHASE3","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2025-02-28","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD","enrollment":284},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT02462889","phase":"PHASE2","title":"IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD","status":"COMPLETED","sponsor":"Jeffrey S Heier","startDate":"2015-06","conditions":"Age-Related Macular Degeneration","enrollment":128},{"nctId":"NCT04522167","phase":"PHASE3","title":"Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-07-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":434},{"nctId":"NCT06591598","phase":"PHASE4","title":"A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-09-02","conditions":"Diabetic Macular Edema, Neovascular Age-related Macular Degeneration","enrollment":51},{"nctId":"NCT06116890","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-31","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":180},{"nctId":"NCT06116916","phase":"PHASE2","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-01-09","conditions":"Diabetic Macular Edema (DME)","enrollment":150},{"nctId":"NCT06769412","phase":"","title":"A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-01","conditions":"Retinal Vasculitis","enrollment":550000},{"nctId":"NCT06556368","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kodiak Sciences Inc","startDate":"2024-08-23","conditions":"Wet Age-related Macular Degeneration","enrollment":675},{"nctId":"NCT02159989","phase":"PHASE1","title":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-06-18","conditions":"Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":83},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT05381948","phase":"PHASE2","title":"Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2022-06-30","conditions":"Wet Age-related Macular Degeneration","enrollment":161},{"nctId":"NCT04015180","phase":"PHASE3","title":"Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-18","conditions":"Retinopathy of Prematurity (ROP)","enrollment":100},{"nctId":"NCT07105228","phase":"","title":"Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-15","conditions":"Retinal Vasculitis","enrollment":290000},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT03712904","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2019-08-09","conditions":"Uveal Melanoma","enrollment":3},{"nctId":"NCT05930561","phase":"PHASE2","title":"4D-150 in Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2023-08-09","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":72},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT06850571","phase":"PHASE4","title":"Aflibercept and Bevacizumab for Diabetic Maculopathies","status":"RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-02-20","conditions":"Diabetic Maculopathy","enrollment":102},{"nctId":"NCT04567550","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-11-20","conditions":"Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)","enrollment":139},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":"Diabetic Macular Edema, Cataract","enrollment":16},{"nctId":"NCT00532155","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Carcinoma, Non Small Cell Lung","enrollment":913},{"nctId":"NCT04270747","phase":"PHASE3","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-06-22","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":576},{"nctId":"NCT05511038","phase":"PHASE4","title":"A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-08-26","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT06672536","phase":"PHASE1, PHASE2","title":"Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2024-11-26","conditions":"nAMD","enrollment":82},{"nctId":"NCT03803631","phase":"","title":"CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2018-04-04","conditions":"AMD, Exudative Macular Degeneration","enrollment":49},{"nctId":"NCT04423718","phase":"PHASE3","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1011},{"nctId":"NCT05536973","phase":"PHASE2","title":"Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2022-08-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":69},{"nctId":"NCT07129239","phase":"PHASE3","title":"High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","status":"NOT_YET_RECRUITING","sponsor":"Clinique de Retine de l'est","startDate":"2025-08-20","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":180},{"nctId":"NCT02556229","phase":"PHASE2","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-06","conditions":"Inflammatory Choroidal Neovascularization","enrollment":20},{"nctId":"NCT04429503","phase":"PHASE2, PHASE3","title":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-29","conditions":"Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT02257502","phase":"PHASE2","title":"Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-07-06","conditions":"Idiopathic Choroidal Neovascularization","enrollment":20},{"nctId":"NCT06011798","phase":"PHASE2","title":"Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2023-08-23","conditions":"Diabetic Macular Edema, Retinal Disease, Macular Edema","enrollment":52},{"nctId":"NCT04757636","phase":"PHASE3","title":"OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":998},{"nctId":"NCT07096713","phase":"NA","title":"Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-01-01","conditions":"Anti-VEGF Therapy","enrollment":38},{"nctId":"NCT05891548","phase":"PHASE2","title":"Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Clearside Biomedical, Inc.","startDate":"2023-05-31","conditions":"Neovascular Age-related Macular Degeneration","enrollment":60},{"nctId":"NCT03823287","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-02-19","conditions":"Wet Macular Degeneration","enrollment":671},{"nctId":"NCT07074054","phase":"","title":"Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes","status":"COMPLETED","sponsor":"Federico II University","startDate":"2024-04-15","conditions":"Presence of Retinal Fluid, Changes in Macular Pigment Optical Density","enrollment":40},{"nctId":"NCT03823300","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-03-11","conditions":"Wet Macular Degeneration","enrollment":658},{"nctId":"NCT03622580","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-05","conditions":"Diabetic Macular Edema","enrollment":940},{"nctId":"NCT03622593","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-09","conditions":"Diabetic Macular Edema","enrollment":951},{"nctId":"NCT04418427","phase":"PHASE2","title":"ADVM-022 Intravitreal Gene Therapy for DME","status":"COMPLETED","sponsor":"Adverum Biotechnologies, Inc.","startDate":"2020-05-28","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":36},{"nctId":"NCT06662994","phase":"PHASE4","title":"High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy","status":"RECRUITING","sponsor":"Retina Consultants of Orange County","startDate":"2025-07-07","conditions":"Diabetic Macular Edema (DME)","enrollment":15},{"nctId":"NCT06198413","phase":"PHASE1","title":"LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2023-02-27","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":12},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT06845163","phase":"PHASE2","title":"Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-08","conditions":"Diabetic Macular Edema, Center-involved Diabetic Macular Edema","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eylea (anti-VEGF agent)","EYLEA"],"phase":"marketed","status":"active","brandName":"Aflibercept (Eylea)","genericName":"Aflibercept (Eylea)","companyName":"Ahmad Zeeshan Jamil","companyId":"ahmad-zeeshan-jamil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting their pro-angiogenic signaling. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}